12th Congress of the European Hematology ... - Haematologica

1492
FREQUENCY OF MEDITERRANEAN GLUCOSE-6-PHOSPHATE DEHYDROGENASE
MUTATION IN SAUDI ARABIA-JEDDAH
M. Gari, A. Chaudhary, A. Abuzenadah, M. Al-Qahtni, F. Al-Says,
A. Al-Harbi, G. Damanouri, G. Damanhouri, S. Lari
King Abdulaziz University, JEDDAH, Saudi Arabia
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a widespread
abnormality of red cell enzyme, which gives rise to hemolysis
under oxidative stress. In Saudi Arabia, however, G6PD deficiency has
a variable frequency in different regions. The prevalence and genotypes
of G6PD deficiency are not known until now in Jeddah province.
Accordingly, we design this study to investigate the frequency of the
Mediterranean mutation that involves exon 6 and exon 7 of the G6PD
gene. 47 samples were collected in a short period from July 2005 to
October 2005. Twenty five Saudi males and 22 Saudi females, (their
ages ranged between 18 and 45) were screened for G6PD deficiency by
quantitative spectrophotometric assay at the Maternity and Children
Hospital in Jeddah for premarital screening were found to be deficient
in G6PD. The DNA of the G6PD deficient subjects was extracted from
whole blood and then amplified by the polymerase chain reaction
(PCR). Mutation analysis was performed by using conformation sensitive
gel electrophoresis (CSGE), altered CSGE patterns were then
sequenced by automated sequencer. All mutations were detected in
exon 6 of the G6PD gene, while no mutations were detected in exon 7.
In conclusion, Mutations were detected in 7/47 G6PD deficient (6
Mediterranean mutation and one Siberian mutation not been reported
in Saudi Arabia). The frequency of Mediterranean mutation in G6PD
patients in Saudi Arabia-Jeddah was 10.3%. This can be used as screening
method for early detection of G6PD deficiency before marriage. In
addition, other G6PD mutations remain to be determined.
1493
THE EFFICIENCY OF ERYTHROPOIETIN ADMINISTERED AT THE ANEMIC PATIENTS WITH
MALIGNANT HEMOPATHIES AND SOLID TUMORS, TREATED WITH CHEMOTHERAPY
R. Mihaila, 1 R. Mihaila, 2 E.C. Rezi, 3 L. Tiurean, 3 M. Deac, 2 A. Catana, 3
M. Patran, 3 L. Draghila, 3 A. Olteanu, 3 L. Mocanu, 3 A. Zaharie, 3
I. Zaharie3 1 Public Health Authority, SIBIU, Romania; 2 Lucian Blaga University, SIBIU,
Romania; 3 Departmental Clinical Hospital, SIBIU, Romania
Background. The treatment of the anemia at the patients with malignancies
combats the hypoxia, improves the answer to the treatment and
ameliorates the quality of life. Aim. We proposed ourselves to study the
efficiency of the Erythropoietin administration at the anemic patients
with malignant hemopathies and solid tumors, treated with chemotherapy.
Method. We have studied all the 57 patients which were in the evidence
of the County Clinical Hospital from Sibiu with malignant
hemopathies and solid tumors, treated with chemotherapy, to which
we have associated Erythropoietin during 15.09.2006-31.12.2006. For all
the patients the informed consent was obtained. We have analyzed the
next parameters: age, gender, the doze of Erythropoietin, the treatment’s
duration and the monthly changes of the hemogram (hemoglobin,
hematocrit, leucocytes and platelets). There was analyzed the
answer at the treatment with Erythropoietin at the patients with malignant
hemopathies compared with those with solid tumors. The variation
of the hematological parameters was statistically analyzed using
the t Student test. Results. The medium age of the group was
60.68±11.64 years. The gender repartition was: 38 women and 19 men.
Only 37 patients could have been evaluated after at least one month of
treatment. The average of the Erythropoietin dose they have used was
30000 UI weekly. The medium duration of the treatment was 7.54
weeks. After a month of treatment the average increasing of the hemoglobin
level was 1.43 g/dL (p